Most Read Articles
Dr Margaret Shi, 13 Jul 2020

An MRI-first diagnostic pathway, combined with risk-tailored screening, is shown to improve the benefit-to-harm profile and cost-effectiveness of screening for prostate cancer (PCa), according to results of a recent lifetable modelling study presented at AACR 2020 Virtual Meeting II.

Christina Lau, 14 Jul 2020

Flat-dose nivolumab, administered as a 30-minute infusion, is well tolerated and active in Asian patients with previously treated advanced non-small-cell lung cancer (NSCLC), according to results of the phase IIIb CheckMate 870 study.

Natalia Reoutova, 17 Jul 2020

At a median follow-up of 22.9 months, atezolizumab plus carboplatin and etoposide (CP/ET), given as a first-line treatment, continued to demonstrate an improvement in overall survival (OS) vs placebo plus CP/ET in patients with extensive-stage small-cell lung cancer (ES-SCLC), according to updated results of the IMpower133 trial presented at the American Association for cancer Research (AACR) 2020 Virtual Annual Meeting II.

12 Jun 2020
Drawing from experience as a key investigator in landmark clinical trials (including PALOMA, MONALEESA and MONARCH), and his clinical experience with CDK4/6 inhibitors, Dr Rafael Villanueva Vázquez shares his insights into the current evidence of using CDK4/6 inhibitors to treat HR+/HER2- ABC.

Gout not a risk factor for colorectal cancer

08 Nov 2019

Individuals with and without gout appear to have a similar risk of developing colorectal cancer, suggesting that gout does not contribute to a risk increase, a study has found.

Researchers used data from the Taiwan National Health Insurance Research Database, identifying 28,061 gout patients (mean age, 53.4 years) and 84,248 matched controls (mean age, 51.1 years) without the medical condition.

Compared with controls, gout patients were more likely to have comorbidities, including hypertension (48.4 percent vs 24.2 percent; p<0.0001), diabetes mellitus (22.4 percent vs 12.3 percent; p<0.0001) and hyperlipidaemia (35.0 percent vs 14.7 percent; p<0.0001).

Over 13 years of follow-up, colorectal cancer occurred with greater frequency in the gout cohort. The incidence rate per 1,000 person-years was 2.44 as compared with 2.13 in the control cohort (incidence rate ratio, 1.15, 95 percent confidence interval [CI], 1.04–1.26). 

However, in a Cox proportional hazards model adjusted for age, gender, urbanization status and comorbidities, gout was not significantly associated with increased risk of incident colorectal cancer (adjusted hazard ratio [HR], 1.03, 95 percent CI, 0.93–1.14).

The researchers additionally conducted a posterior analysis comparing colorectal cancer risk between gout patients with and without prescriptions for allopurinol. Results indicated a weak inverse association between allopurinol and the cancer risk (HR, 0.95, 95 percent CI, 0.80–1.12), although the analysis was not controlled for risk factors for colorectal cancer.

Therefore, additional pharmaco-epidemiological studies are needed to establish whether allopurinol plays a role in preventing the development of colorectal cancer in patients with gout, according to the researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr Margaret Shi, 13 Jul 2020

An MRI-first diagnostic pathway, combined with risk-tailored screening, is shown to improve the benefit-to-harm profile and cost-effectiveness of screening for prostate cancer (PCa), according to results of a recent lifetable modelling study presented at AACR 2020 Virtual Meeting II.

Christina Lau, 14 Jul 2020

Flat-dose nivolumab, administered as a 30-minute infusion, is well tolerated and active in Asian patients with previously treated advanced non-small-cell lung cancer (NSCLC), according to results of the phase IIIb CheckMate 870 study.

Natalia Reoutova, 17 Jul 2020

At a median follow-up of 22.9 months, atezolizumab plus carboplatin and etoposide (CP/ET), given as a first-line treatment, continued to demonstrate an improvement in overall survival (OS) vs placebo plus CP/ET in patients with extensive-stage small-cell lung cancer (ES-SCLC), according to updated results of the IMpower133 trial presented at the American Association for cancer Research (AACR) 2020 Virtual Annual Meeting II.

12 Jun 2020
Drawing from experience as a key investigator in landmark clinical trials (including PALOMA, MONALEESA and MONARCH), and his clinical experience with CDK4/6 inhibitors, Dr Rafael Villanueva Vázquez shares his insights into the current evidence of using CDK4/6 inhibitors to treat HR+/HER2- ABC.